AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$37.94 USD
-1.48 (-3.75%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $37.95 +0.01 (0.03%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$37.94 USD
-1.48 (-3.75%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $37.95 +0.01 (0.03%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth D Momentum B VGM
Zacks News
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.
Here's Why You Should Hold on to CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to gain momentum from a solid product portfolio and strong General Surgery business. However, data security threats linger.
Teleflex (TFX) Hurt by Urolift Cancellations, Cost Woes
by Zacks Equity Research
Teleflex (TFX) continues to face supply-chain challenges and freight logistic delays.
Reasons to Add Quidel (QDEL) Stock To Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Quidel (QDEL) owing to its strong diagnostics portfolio.
STERIS (STE) Strategic Buyouts Aid Growth, Margin Woe Stays
by Zacks Equity Research
STERIS' (STE) significant revenues from acquisitions of Key Surgical and Cantel Medical appear promising.
Cardiovascular Systems (CSII) Finances New DCB Development
by Zacks Equity Research
Per the terms of the deal, Cardiovascular Systems (CSII) is providing milestone-based financing to CVT for the development of coronary and peripheral DCBs.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Medtronic (MDT) Inks Deal to Offer Touch Surgery Enterprise
by Zacks Equity Research
Medtronic's (MDT) Touch Surgery Enterprise gives surgical teams a powerful new tool to enhance patient care by simplifying the process to capture and analyze surgical videos.
Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Nevro's (NVRO) PDN Therapy Gets Noridian's Medicare Coverage
by Zacks Equity Research
Latest favorable coverage decision for Nevro's (NVRO) PDN Therapy by Noridian is expected to allow the former to serve a wider patient pool.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
Accuray's (ARAY) CyberKnife S7 System Gets Chosen by CARTI
by Zacks Equity Research
Accuray's (ARAY) CyberKnife S7 System gets selected by the CARTI medical care team, thereby offering better cancer care in Arkansas via expanded access to advanced technology.
Here's Why You Should Retain Charles River (CRL) Stock For Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on robust demand in Biologics Testing Solutions and Microbial Solutions businesses.
Allscripts (MDRX) Up 4.5% Since Q4 Earnings: What's Driving It?
by Zacks Equity Research
Allscripts' (MDRX) stock rallies on better-than-expected fourth-quarter performance and recent alliances.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
Merit Medical's (MMSI) Product Included in FDA's Program
by Zacks Equity Research
Receipt of the Breakthrough Device Designation for Merit Medical's (MMSI) Embosphere Microspheres is expected to improve patient outcome.
Walgreens (WBA) Expands Access to COVID-19 Test With LabCorp
by Zacks Equity Research
Walgreens (WBA) will enable more communities to access reliable, convenient testing services as and when required with the addition of Pixel by LabCorp COVID-19 at-home collection kit.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.
PacBio (PACB) Supports SickKids With Sequencing Technology
by Zacks Equity Research
PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.
Zacks.com featured highlights include AutoNation, Asbury Automotive Group, AMN Healthcare Services, Teck Resources and AGCO
by Zacks Equity Research
AutoNation, Asbury Automotive Group, AMN Healthcare Services, Teck Resources and AGCO are included in this blog.
AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.
Catalent's (CTLT) New Tie-Up to Provide Better Patient Access
by Zacks Equity Research
Catalent's (CTLT) latest collaboration is expected to enable it to provide customers access to the TFF technology.
Chemed (CHE) Roto-Rooter Sales Robust Despite COVID-19 Woes
by Zacks Equity Research
Chemed's (CHE) Roto-Rooter business gains from growing demand for plumbing, drain cleaning and excavation and water restoration services.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on solid recovery in most of its key global markets as well as an uptick in demand for COVID-related products.
Dexcom's (DXCM) CGM Gets FDA's Breakthrough Device Designation
by Zacks Equity Research
Dexcom's (DXCM) CGM's use in the hospital setting is likely to be more effective in glycemic management and improved patient outcomes.